FDA Approves Cymbalta For New Indication

摘要

Eli Lilly has received FDA approval to expand Cymbalta's generalized anxiety disorder (GAD) indication for maintenance treatment of the condition in adults.rnCymbalta (duloxetine HC1) is approved for acute treatment of the disorder in adults, and also for major depressive disorder, management of diabetic peripheral neuropathic pain and fibromyal-gia, the company says in a statement last week.rnApproval for the new indication was based on a double-blind, placebo-controlled trial of 429 patients who initially had responded to maintenance treatment with Cymbalta for GAD during a 26-week open-label phase of the trial.